Zotatifin Drug Asset Due Diligence Report 2026

This Zotatifin Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 3 August 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Phase 2

Highest phase

Registered trials

Result records

Matched deals

Executive recommendation: CONDITIONAL GO

Decision memo

Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.

The central underwriting question is whether Zotatifin can convert its Small molecule drug profile and eIF4A biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Zotatifin (query alias: Zotatifin)
Modality / target	Small molecule drug; eIF4A; eIF4A inhibitors
Highest global status	Phase 2
Originator	eFFECTOR Therapeutics, Inc.
Active developers	eFFECTOR Therapeutics Operations, Inc., eFFECTOR Therapeutics, Inc.

The MCP disease footprint includes Estrogen receptor positive breast cancer, KRAS mutant Non-small Cell Lung Cancer, ER-positive/HER2-negative Breast Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
NCT05101564	Phase 2	Completed	19	Percentage Change in Ki67
NCT04092673	Phase 1/2	Unknown status	30	Parts 1a and 1b: MTD
NCT04632381	Phase 1	Completed	36	Safety as assessed by the incidence of Treatment Emergent Adverse Events and Serious Adverse Events

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

An Umbrella, Randomized, Controlled, Pre Operative Trial Testing Integrative Subtype Targeted Therapeutics in Estrogen Receptor Positive, HER2-Negative Breast Cancer

Phase 2; n=19; evaluation: not stated. Reported fields: -; Percentage Change in Ki67(Mean) = -0.68 percentage (95% Confidence Interval, -3.99 to 2.64); -

Phase 1/2 dose expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with ER+ metastatic breast cancer.

Phase 1/2; n=36; evaluation: Positive. Reported fields: AE(grade 3/4) = 21 % ; AE(grade 3/4) = 28 %

First-in-human phase 1/2 dose escalation and expansion study evaluating first-in-class eIF4A inhibitor zotatifin in patients with solid tumors.

Phase 1/2; n=53; evaluation: Positive. Reported fields: RP2D = 0.07 mg/kg

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Zotatifin addresses Estrogen receptor positive breast cancer, KRAS mutant Non-small Cell Lung Cancer, ER-positive/HER2-negative Breast Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 1 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: eIF4A records as comparable precedents only.

Date	Transaction	Phase at deal	Disclosed economics
2021-11-18	Aglaia Therapeutics becomes Ribonexus and signs exclusive license agreement with Pierre Fabre on small molecules targeting eIF4A, an innovative target in oncology	Preclinical	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “EIF4a inhibitor combinations”. The milestone feed surfaced a patent-application signal described as “Eif4-a-inhibiting compounds and methods related thereto”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

CONDITIONAL GO